Investment analysts at TD Cowen began coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The brokerage set a “buy” rating on the stock.
RAPP has been the subject of several other research reports. Stifel Nicolaus began coverage on shares of Rapport Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 target price for the company. Jefferies Financial Group started coverage on shares of Rapport Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $35.00 price target for the company.
Read Our Latest Stock Analysis on RAPP
Rapport Therapeutics Price Performance
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- Find and Profitably Trade Stocks at 52-Week Lows
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- NYSE Stocks Give Investors a Variety of Quality Options
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
